Autor: |
Urmancheeva AF; Medical Academy for Further Education, St. Petersburg., Ul'rikh EA, Neustadt EL, Zel'dovich DR, Dikareva AV |
Jazyk: |
ruština |
Zdroj: |
Voprosy onkologii [Vopr Onkol] 2002; Vol. 48 (6), pp. 679-83. |
Abstrakt: |
The share of seroso-papillary endometrial carcinoma (SPEC) for the past 4 years has been 6.4%--101 out of 1,567 endometrial cancers. There has been lower incidence of obesity, diabetes mellitus and infertility in cases of SPEC than endometrioid carcinoma (EEC)--18.8 and 53.7; 12.9 and 23.3; 8.8 and 20.6%, respectively, (p < 0.05). Only 60.4% of SPEC patients had locally-advanced tumors (stage I--35.6; stage II--24.8%) while tumor dissemination was reported in 39.6% (stage III--27.7 and stage IV--11.9%). Among EEC patients, locally-advanced tumors were detected in 89.6% (stage I--62.9 and stage II--26.7%) and disseminated tumor incidence was 3 times lower than in SPEC--10.4% (stage III--8.1 and stage IV--2.3%). Deep invasion into the stroma (more than 10 mm) was registered in 27.7% (SPEC) while in EEC--6.0% (p(0.05). Lymphogenous metastasis was much more common in SPEC (13.9%) as compared with less than 4.1% in EEC patients. There was no correlation between its presence and depth of invasion in the myometrium (p(0.05). High incidence of association of metastasis and superficial or deep invasion was reported for SPEC. This tumor should be classified as pathogenetic variant II of clinico-morphological changes. |
Databáze: |
MEDLINE |
Externí odkaz: |
|